Phase 2 Study on Zanubrutinib and BGB-11417 Efficacy and Tolerance in Previously Treated Waldenström Macroglobulinemia Patients

The primary objective of this study is to evaluate the **efficacy** and **tolerance** of a combination therapy consisting of zanubrutinib and BGB-11417 in patients with Waldenström macroglobulinemia who have previously undergone at least one line of treatment. This is clinically relevant as it aims to provide insights into potential therapeutic options for patients with this condition, which is characterized by its indolent nature and the need for effective management strategies following initial treatment failure or relapse.

The clinical trial involves **patients with Waldenstrom macroglobulinemia** who have received at least one prior line of treatment. The study population includes both male and female participants, with an age range encompassing adults and older adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their medical condition and treatment history. No specific lifestyle considerations such as diet, physical activity, or habits have been highlighted as relevant to the study. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed to evaluate the efficacy and tolerance of a combination therapy in patients with **Waldenstrom macroglobulinemia** who have received at least one prior line of treatment. This study is structured as an open-label, phase 2 trial, with an estimated recruitment start date of June 1, 2024, and an anticipated completion by December 31, 2030. Participants will be involved in a series of study visits, beginning with an inclusion visit to assess eligibility based on predefined criteria. This initial screening will ensure that only suitable candidates are enrolled in the trial.

Following the inclusion visit, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and any potential adverse effects. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment regimen. The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, but it is anticipated to span several months.

Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or if the investigator deems it in the best interest of the participant's health. The trial's methodology ensures that data collected is robust and reliable, contributing valuable insights into the treatment of Waldenstrom macroglobulinemia. The study's design and procedures are meticulously planned to uphold the highest standards of clinical research, ensuring the safety and well-being of all participants throughout the trial duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it is classified as an orphan drug. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for any non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy within the context of a Phase 4 study. The trial is scheduled to commence recruitment on June 1, 2024, with an estimated completion date of December 31, 2030. The efficacy assessment will be conducted in accordance with the trial's protocol, which is aligned with the standards for Phase 4 trials. Although specific efficacy parameters, such as primary and secondary endpoints, are not detailed, the trial will likely employ validated methods and instruments typical of this phase to evaluate outcomes. The analysis will be conducted at predetermined intervals throughout the trial duration, ensuring a comprehensive evaluation of the treatment's efficacy. The trial's design will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy data collected.